Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Vanessa ArcieroJin LuoAmbica ParmarWei Fang DaiJaclyn M BecaMichael J RaphaelWanrudee IsaranuwatchaiSteven HabbousMina TadrousCraig C EarleJim J BiagiNicole MittmannJessica AriasScott GavuraKelvin Kar-Wing ChanPublished in: JNCI cancer spectrum (2022)
Gem-Nab is likely more costly and less effective than FOLFIRINOX and therefore not considered cost-effective at commonly accepted willingness-to-pay thresholds.